<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00850707</url>
  </required_header>
  <id_info>
    <org_study_id>VASACC2009-02</org_study_id>
    <nct_id>NCT00850707</nct_id>
  </id_info>
  <brief_title>Vascular Access for Hemodialysis and Inflammation</brief_title>
  <official_title>Artero-Venous Fistula, Prosthetic Polytetrafluoroethylene Grafts (AVG), Tunneled Cuffed Catheter (TCC): Impact of Vascular Access on HD Inflammation and Monocyte Activation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Orsola Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Orsola Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study was to investigate patients free of active infection and/or
      thrombosis to assess if the type of vascular access (AVF, AVG, TCC), could influence:

        1. the levels of serological markers of inflammation (CRP, IL-6, TNF-a);

        2. the degree of expression on monocyte surface of inflammation and immune response
           modulating molecules: CD14, CD32 and CD44.

        3. the amount of monocytic cells expressing a senescent phenotype (CD14 and CD32).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with AVF assumed ticlopidine 250 mg/die, patients with TCC and AVG assumed warfarin
      to maintain target INR between 1.8 and 2.5.

      Six wash out consecutive sessions were carried out before starting the study with Fresenius
      FX8 Helyxone® , for patients who underwent HD, or with FX 80 Helyxone®, for patients who
      underwent hemodiafiltration (HDF). After the wash out period, fresh whole blood and serum
      samples were drawn on starting dialysis, during the midweek HD session for 4 consecutive
      weeks. For each patient the mean value of the 4 blood samples was considered. All patients
      continued HD or HDF with FX8 or FX 80 Helyxone® during the whole study period.In order to
      estimate the normal ranges of the parameters that we evaluated, 60 anonymous healthy
      volunteers were also submitted to the same assays.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2000</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>serological markers of inflammation (CRP, IL-6, TNF-a)</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>monocyte surface of inflammation and immune response modulating molecules: CD14, CD32 and CD44.</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>monocytic cells expressing a senescent phenotype (CD14 and CD32).</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">458</enrollment>
  <condition>Vascular Access for Hemodialysis and Inflammation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>220 hemodialysis patients with Arterovenous fistula (AVF group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>58 hemodialysis patients with Arterovenous graft (AVG group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>180 hemodialysis patients with Tunneled cuffed catheters (TCC group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <description>60 healthy subjects as controls</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The three groups of patients were homogeneous for: a) demographic characteristics; b)
        dialysis adequacy; c) vascular access blood flow; d) white cell count.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All the patients recruited for the study were infection and thrombosis free from
             almost 6 months.

          -  No patients included had autoimmune disease, hepatic failure, diabetes or malignancy.

          -  Patients were not administered ACE inhibitors, angiotensin receptor antagonists,
             antiinflammatory or immunosuppressive drugs.

          -  All the patients had residual GFR &lt; 5 ml/min.

          -  The vascular access considered were placed from at least 6 months.

        Exclusion Criteria:

          -  Patients with recirculating vascular access &gt; 10% were excluded from the study.

          -  Patients with acute cardiovascular accident in the last 15 days before starting the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nephrology Dialysis Transplantation Unit St.Orsola University Hospital</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD. Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis. 2003 Nov;42(5):864-81. Review.</citation>
    <PMID>14582032</PMID>
  </reference>
  <reference>
    <citation>Weiss MF, Scivittaro V, Anderson JM. Oxidative stress and increased expression of growth factors in lesions of failed hemodialysis access. Am J Kidney Dis. 2001 May;37(5):970-80.</citation>
    <PMID>11325679</PMID>
  </reference>
  <reference>
    <citation>Nilsson B, Ekdahl KN, Mollnes TE, Lambris JD. The role of complement in biomaterial-induced inflammation. Mol Immunol. 2007 Jan;44(1-3):82-94. Epub 2006 Aug 14. Review.</citation>
    <PMID>16905192</PMID>
  </reference>
  <reference>
    <citation>Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH, Rubin AL. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis. 1998 Jul;32(1):107-14.</citation>
    <PMID>9669431</PMID>
  </reference>
  <reference>
    <citation>Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999 Feb;55(2):648-58.</citation>
    <PMID>9987089</PMID>
  </reference>
  <reference>
    <citation>Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2000 Mar;35(3):469-76.</citation>
    <PMID>10692273</PMID>
  </reference>
  <reference>
    <citation>Ramírez R, Carracedo J, Soriano S, Jiménez R, Martín-Malo A, Rodríguez M, Blasco M, Aljama P. Stress-induced premature senescence in mononuclear cells from patients on long-term hemodialysis. Am J Kidney Dis. 2005 Feb;45(2):353-9.</citation>
    <PMID>15685514</PMID>
  </reference>
  <reference>
    <citation>Carracedo J, Ramírez R, Madueño JA, Soriano S, Rodríguez-Benot A, Rodríguez M, Martín-Malo A, Aljama P. Cell apoptosis and hemodialysis-induced inflammation. Kidney Int Suppl. 2002 May;(80):89-93. Review.</citation>
    <PMID>11982820</PMID>
  </reference>
  <reference>
    <citation>Kielian TL, Blecha F. CD14 and other recognition molecules for lipopolysaccharide: a review. Immunopharmacology. 1995 Apr;29(3):187-205. Review.</citation>
    <PMID>7542643</PMID>
  </reference>
  <reference>
    <citation>Patiño R, Ibarra J, Rodriguez A, Yagüe MR, Pintor E, Fernandez-Cruz A, Figueredo A. Circulating monocytes in patients with diabetes mellitus, arterial disease, and increased CD14 expression. Am J Cardiol. 2000 Jun 1;85(11):1288-91.</citation>
    <PMID>10831941</PMID>
  </reference>
  <reference>
    <citation>Ramirez R, Carracedo J, Berdud I, Carretero D, Merino A, Rodríguez M, Tetta C, Martín-Malo A, Aljama P. Microinflammation in hemodialysis is related to a preactivated subset of monocytes. Hemodial Int. 2006 Jan;10 Suppl 1:S24-7.</citation>
    <PMID>16441864</PMID>
  </reference>
  <reference>
    <citation>Tacke F, Randolph GJ. Migratory fate and differentiation of blood monocyte subsets. Immunobiology. 2006;211(6-8):609-18. Epub 2006 Jul 10. Review.</citation>
    <PMID>16920499</PMID>
  </reference>
  <reference>
    <citation>Puré E, Cuff CA. A crucial role for CD44 in inflammation. Trends Mol Med. 2001 May;7(5):213-21. Review.</citation>
    <PMID>11325633</PMID>
  </reference>
  <reference>
    <citation>Gee K, Lim W, Ma W, Nandan D, Diaz-Mitoma F, Kozlowski M, Kumar A. Differential regulation of CD44 expression by lipopolysaccharide (LPS) and TNF-alpha in human monocytic cells: distinct involvement of c-Jun N-terminal kinase in LPS-induced CD44 expression. J Immunol. 2002 Nov 15;169(10):5660-72.</citation>
    <PMID>12421945</PMID>
  </reference>
  <reference>
    <citation>Movilli E, Brunori G, Camerini C, Vizzardi V, Gaggia P, Cassamali S, Scolari F, Parrinello G, Cancarini GC. The kind of vascular access influences the baseline inflammatory status and epoetin response in chronic hemodialysis patients. Blood Purif. 2006;24(4):387-93. Epub 2006 Jun 1.</citation>
    <PMID>16755161</PMID>
  </reference>
  <reference>
    <citation>Chang CJ, Ko YS, Ko PJ, Hsu LA, Chen CF, Yang CW, Hsu TS, Pang JH. Thrombosed arteriovenous fistula for hemodialysis access is characterized by a marked inflammatory activity. Kidney Int. 2005 Sep;68(3):1312-9.</citation>
    <PMID>16105066</PMID>
  </reference>
  <reference>
    <citation>Raad I, Costerton W, Sabharwal U, Sacilowski M, Anaissie E, Bodey GP. Ultrastructural analysis of indwelling vascular catheters: a quantitative relationship between luminal colonization and duration of placement. J Infect Dis. 1993 Aug;168(2):400-7.</citation>
    <PMID>8335977</PMID>
  </reference>
  <reference>
    <citation>Beathard GA, Urbanes A. Infection associated with tunneled hemodialysis catheters. Semin Dial. 2008 Nov-Dec;21(6):528-38. doi: 10.1111/j.1525-139X.2008.00497.x. Epub 2008 Sep 24.</citation>
    <PMID>19000122</PMID>
  </reference>
  <reference>
    <citation>Kaysen GA. The microinflammatory state in uremia: causes and potential consequences. J Am Soc Nephrol. 2001 Jul;12(7):1549-57. Review.</citation>
    <PMID>11423586</PMID>
  </reference>
  <reference>
    <citation>Ayus JC, Sheikh-Hamad D. Silent infection in clotted hemodialysis access grafts. J Am Soc Nephrol. 1998 Jul;9(7):1314-7.</citation>
    <PMID>9644644</PMID>
  </reference>
  <reference>
    <citation>Roy-Chaudhury P, Kelly BS, Miller MA, Reaves A, Armstrong J, Nanayakkara N, Heffelfinger SC. Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts. Kidney Int. 2001 Jun;59(6):2325-34.</citation>
    <PMID>11380837</PMID>
  </reference>
  <reference>
    <citation>Oliver MJ, Mendelssohn DC, Quinn RR, Richardson EP, Rajan DK, Pugash RA, Hiller JA, Kiss AJ, Lok CE. Catheter patency and function after catheter sheath disruption: a pilot study. Clin J Am Soc Nephrol. 2007 Nov;2(6):1201-6. Epub 2007 Oct 17.</citation>
    <PMID>17942775</PMID>
  </reference>
  <reference>
    <citation>Daneshian M, Wendel A, Hartung T, von Aulock S. High sensitivity pyrogen testing in water and dialysis solutions. J Immunol Methods. 2008 Jul 20;336(1):64-70. doi: 10.1016/j.jim.2008.03.013. Epub 2008 Apr 24.</citation>
    <PMID>18474369</PMID>
  </reference>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2009</study_first_submitted>
  <study_first_submitted_qc>February 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2009</study_first_posted>
  <last_update_submitted>February 26, 2009</last_update_submitted>
  <last_update_submitted_qc>February 26, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 27, 2009</last_update_posted>
  <responsible_party>
    <name_title>Prof.Sergio Stefoni</name_title>
    <organization>St.Orsola University Hospital</organization>
  </responsible_party>
  <keyword>AVF</keyword>
  <keyword>AVG</keyword>
  <keyword>TCC</keyword>
  <keyword>inflammation</keyword>
  <keyword>monocite senescence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

